Free Trial

GoodRx Q2 2023 Earnings Report

GoodRx logo
$4.77 -0.18 (-3.64%)
As of 01/31/2025 04:00 PM Eastern

GoodRx EPS Results

Actual EPS
$0.02
Consensus EPS
$0.01
Beat/Miss
Beat by +$0.01
One Year Ago EPS
N/A

GoodRx Revenue Results

Actual Revenue
$189.68 million
Expected Revenue
$186.90 million
Beat/Miss
Beat by +$2.78 million
YoY Revenue Growth
N/A

GoodRx Announcement Details

Quarter
Q2 2023
Time
N/A

Conference Call Resources

Conference Call Audio

Slide Deck

GoodRx Earnings Headlines

TD Cowen Sticks to Its Buy Rating for GoodRx Holdings (GDRX)
Alert: DOGE goes live
"It's Elon's world, and the rest of us live in it." Every investor in America is trying to figure out what he might do next. And one widely followed Boston based think tank is stepping forward with their official playbook.
See More GoodRx Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like GoodRx? Sign up for Earnings360's daily newsletter to receive timely earnings updates on GoodRx and other key companies, straight to your email.

About GoodRx

GoodRx (NASDAQ:GDRX), together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices. It also offers other healthcare products and services, including subscriptions, and pharma manufacturer solutions, as well as telehealth services through the GoodRx Care platform. It serves pharmacy benefit managers who manage formularies and prescription transactions, including establishing pricing between consumers and pharmacies. The company was founded in 2011 and is headquartered in Santa Monica, California.

View GoodRx Profile

More Earnings Resources from MarketBeat